Retatrutide: what the research actually says

Retatrutide gets discussed alongside approved drugs like Ozempic and Zepbound, and that's understandable, it comes from the same class of research and the same company (Eli Lilly). But it belongs in a different category: it is still an experimental compound moving through the FDA's clinical trial and review process, not a drug you can be legally prescribed today. For how it fits into the broader weight-loss peptide landscape, see our peptides for weight loss overview.

What retatrutide is

Retatrutide (Lilly's internal code LY3437943) is a "triple agonist": a single molecule engineered to activate three separate hormone receptors, GIP, GLP-1, and glucagon, at once. That's one receptor more than tirzepatide (Zepbound/Mounjaro, a dual GIP/GLP-1 agonist) and two more than semaglutide (Ozempic/Wegovy, GLP-1 only). The added glucagon-receptor activity is the mechanistic reason researchers are watching it closely for weight loss and metabolic effects beyond what GLP-1-only drugs produce.

What the trial evidence actually shows

The key published data point is a randomized, placebo-controlled Phase 2 trial in the New England Journal of Medicine, led by Yale's Dr. Ania Jastreboff and colleagues.¹ In 338 adults with obesity, the highest studied dose (12 mg weekly) produced a 24.2% average reduction in body weight at 48 weeks, compared with 2.1% for placebo. At that dose, 83% of participants lost 15% or more of their body weight. The most common side effects were gastrointestinal (nausea and related symptoms), generally mild to moderate and dose-related, alongside a dose-dependent rise in heart rate that peaked around 24 weeks and declined afterward.

Where it actually stands in 2026

Retatrutide has moved into Phase 3, the stage required before an FDA approval decision. A completed Phase 3 trial in people with obesity or overweight is registered on ClinicalTrials.gov (NCT05929066), and multiple other Phase 3 studies, including a cardiovascular and kidney outcomes trial, remain active. A Phase 3 trial in type 2 diabetes, published in The Lancet in June 2026, describes retatrutide as a drug still "under clinical development."² No FDA approval has been granted as of this writing; openFDA's public drug-approval database shows no approved application for retatrutide.

"The interesting thing about GLP-1s is that even with all the research we already have, we're continuing to find even more benefits and risks related to GLP-1s, which may be why there's so much interest in these newer peptides. They hint at promising possibilities."

— Dr. Anthony C. Tam, MD, family and sports medicine physician, Henry Ford Health, in the American Medical Association (April 2026)

Why "not approved yet" still matters

Because retatrutide has not been approved, there is no legal, regulated product you can be prescribed today. Anything marketed online as "retatrutide" outside of a clinical trial is not manufactured under FDA drug oversight, has no verified purity or dosing, and carries the same buyer-beware profile as any other unapproved injectable peptide, regardless of how strong the underlying Phase 2 and Phase 3 science looks. Strong trial data and an approved, prescribable product are two different things until the FDA review is actually complete.

What to do if you're interested

If you want access to a GIP/GLP-1/glucagon-class medication today, the honest options are the ones with completed FDA approval, discussed with a licensed physician who can evaluate whether you're a candidate. For retatrutide specifically, the responsible path is watching for its FDA decision, or asking a doctor about enrolling in an active clinical trial, not sourcing an unregulated version. See are peptides legal for how approval status shapes what's actually available.